10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.13), $0.09 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $166 million versus the consensus estimate of $157.73 million.

GUIDANCE:

10x Genomics sees FY2026 revenue of $600-625 million, versus the consensus of $611.8 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.